ORGANON & CO (OGN) Stock Price, Forecast & Analysis
USA - NYSE:OGN - US68622V1061 - Common Stock
OGN Key Statistics, Chart & Performance
The current stock price of OGN is 7.445 USD. In the past month the price decreased by -14.52%. In the past year, price decreased by -49.54%.
OGN Latest News, Press Relases and Analysis
OGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.69 | 992.51B | ||
| JNJ | JOHNSON & JOHNSON | 19.47 | 486.75B | ||
| MRK | MERCK & CO. INC. | 10.7 | 235.37B | ||
| PFE | PFIZER INC | 7.75 | 140.92B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.99 | 93.35B | ||
| ZTS | ZOETIS INC | 18.19 | 51.11B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.22 | 22.10B | ||
| VTRS | VIATRIS INC | 4.49 | 12.20B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.95 | 10.47B | ||
| CORT | CORCEPT THERAPEUTICS INC | 84.98 | 7.88B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.33B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.25B |
Related stock screener links
About OGN
Company Profile
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Company Info
ORGANON & CO
30 Hudson Street, Fl 33
Jersey City NEW JERSEY US
CEO: Kevin Ali
Employees: 10000
Phone: 15514306000
ORGANON & CO / OGN FAQ
What does OGN do?
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Can you provide the latest stock price for ORGANON & CO?
The current stock price of OGN is 7.445 USD. The price decreased by -3.44% in the last trading session.
Does OGN stock pay dividends?
ORGANON & CO (OGN) has a dividend yield of 1.05%. The yearly dividend amount is currently 1.16.
How is the ChartMill rating for ORGANON & CO?
OGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the valuation of ORGANON & CO (OGN) based on its PE ratio?
The PE ratio for ORGANON & CO (OGN) is 1.96. This is based on the reported non-GAAP earnings per share of 3.79 and the current share price of 7.445 USD.
Should I buy OGN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OGN.
Can you provide the growth outlook for ORGANON & CO?
The Revenue of ORGANON & CO (OGN) is expected to decline by -1.85% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
OGN Technical Analysis
OGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to OGN. OGN scores excellent on profitability, but there are concerns on its financial health.
OGN Financial Highlights
Over the last trailing twelve months OGN reported a non-GAAP Earnings per Share(EPS) of 3.79. The EPS decreased by -7.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.14% | ||
| ROA | 5.19% | ||
| ROE | 95.5% | ||
| Debt/Equity | 11.98 |
OGN Forecast & Estimates
15 analysts have analysed OGN and the average price target is 11.05 USD. This implies a price increase of 48.42% is expected in the next year compared to the current price of 7.445.
For the next year, analysts expect an EPS growth of -5.43% and a revenue growth -1.85% for OGN